Even C.Wang H.-M.Li S.-H.Ngan R.K.-C.Dechaphunkul A.Zhang L.Yen C.-J.Chan P.C.Chakrabandhu S.Ma B.B.Y.Tanasanvimon S.Lee V.H.F.PEI-JEN LOULi Z.Spira A.I.Sukari A.Guigay J.McCune S.Gonzalez-Maffe J.Szpakowski S.Yao Y.Liang H.Mataraza J.Sechaud R.Manenti L.Lim D.W.-T.2022-09-152022-09-1520211078-0432https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120495726&doi=10.1158%2f1078-0432.CCR-21-0822&partnerID=40&md5=142ed4f77572b1e214cd799d072852e0https://scholars.lib.ntu.edu.tw/handle/123456789/620586[SDGs]SDG3Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancerjournal article10.1158/1078-0432.CCR-21-0822344336532-s2.0-85120495726